Beyond the Trial: Real-World Evidence and Lifecycle Evidence Generation in NICE Existing-Use HealthTech Assessments

About this session

ISSUE: As health systems seek to optimise decisions on technologies already embedded in routine care, real-world evidence (RWE) is becoming crucial. NICE's existing-use HealthTech assessments (formerly late-stage assessments, LSA) apply lifecycle thinking to established products, drawing on registry data, claims data, observational studies, and patient-reported outcomes to address what pre-market evidence was not designed to answer.

Speakers

• DL

  Dawn Lee

  University of Exeter PenTAG

  Moderator

• MK

  Michael Kolovetsios

  Johnson & Johnson MedTech

  Panelist

• 

  Stacey Chang-Douglass

  Insira (formerly Clarivate LS&H)

  Panelist

• AC

  Anastasia Chalkidou

  NICE

  Panelist